Publicaciones en las que colabora con Juan Berenguer Berenguer (13)

2023

  1. Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid

    Enfermedades Infecciosas y Microbiologia Clinica

2022

  1. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19

    Journal of Infection

2021

  1. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: The COVID-19 SEIMC score

    Thorax, Vol. 76, Núm. 9, pp. 920-929

  2. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

2018

  1. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real-world practice: Madrid coinfection registry findings

    Hepatology, Vol. 68, Núm. 1, pp. 32-47

  2. Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997–2013): A nationwide population-based study in Spain

    European Journal of Internal Medicine, Vol. 48, pp. 69-74

  3. Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Correction: Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 Week results of the SIMRIKI retrospective study (PLoS ONE (2016) 11:10 (e0164455) DOI: 10.1371/journal.pone.0164455)

    PLoS ONE

2016

  1. Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study

    PLoS ONE, Vol. 11, Núm. 10

2010

  1. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus

    Journal of Acquired Immune Deficiency Syndromes, Vol. 55, Núm. 2, pp. 176-181